皮纹加PRS联合模型增量的「信号谱定位」:增量NRI主要来自哪类皮纹特征与哪个疾病亚组

Written by

in

Language

Evidence level: C

联合模型报告一个总增量是不够的——增量从哪类皮纹特征来、落在哪个亚组上,才是判断这套模型有没有生物学含义的分水岭。

正文

皮纹(指纹与掌部的嵴线构型)在胎儿期第13到19周左右定型,与中枢神经元的迁移共享同一段发育窗口,因此被视为「产前发育扰动的外部读数」。多基因风险评分(PRS)则是从成年基因组直接读出的遗传负载。两者一个记录子宫里发生过什么,一个记录精卵里带来什么——把它们放进同一个预测模型,理论上应该互补。问题是:现在的联合模型研究大多只报告一个总的AUC或NRI增量,从不回答两个更细的问题——增量主要来自哪一类皮纹特征?又主要落在哪一组人身上?

第一个问题有先例可查。一项纳入22项研究的元分析发现,皮纹与精神分裂症的关联谱并不均匀:只有总指纹嵴线数和总A-B嵴线数这两类「计数型」特征达到统计显著(且效应量偏小),而atd角、指型类别、波动不对称等特征均未达显著(PMID 23116885)。更早的病例对照研究进一步示范了「按特征类别拆开算」的做法——把方向性不对称与波动性不对称分开检验,结论是两者贡献结构完全不同(PMID 12659652)。2021年的临床亚型研究也显示,不同亚型对应的皮纹特征组合不一致(PMID 34111156)。换句话说,皮纹信号天然是「有谱的」,把全部特征揉成一团算总增量,等于默认谱是均匀的——这个假设大概率是错的。

第二个问题,心血管PRS文献已经给了标准操作示范:PRS对临床风险模型的增量NRI主要落在「中危」人群——低危者不需要重分类,高危者临床变量已足够,只有中间地带是PRS的用武之地(PMID 36652418、37925478)。还有研究观察到AUC几乎不动但NRI显著为正的「指标错位」现象——增量体现在排序改善而非区分度(PMID 38758931)。照此推理,皮纹的增量在疾病亚组上也应分层核算:早发病例(神经发育扰动窗口更纯)、家族史阳性者(皮纹-遗传负载可能存在交互,家族传递研究已提示皮纹相似度在患病亲子对中异常升高,PMID 40918011)、PRS高分位者(这里可能出现天花板效应:PRS已抓住的方差,皮纹的剩余贡献理应缩水)。

方法上还有一个容易踩的坑:皮纹特征之间高度相关(同一只手的各指嵴线数近乎共线),逐特征做置换重要性会因相关特征互相「顶替」而同时低估,SHAP虽会拆分贡献但结果依赖条件语义的选择。更稳的做法是按特征族做整族消融——「去掉全部嵴线数」「去掉全部不对称指标」逐族进出模型,直接看各族的增量NRI变化,回避逐特征归因的相关性陷阱(PMID 38716264、37726680)。

对易学读者说明一句:手相文化里「看掌纹断命运」属于符号解读,本文讨论的是可计量的皮纹定量特征与疾病风险的统计关联,两者不是一回事。

证据与局限

已验证: 皮纹-精神分裂症关联中,嵴线数类特征效应最稳健(元分析,PMID 23116885);PRS增量NRI集中于中危人群、且可出现AUC不变而NRI显著的现象(PMID 36652418、38758931)。
部分验证: 皮纹特征分类别贡献结构不同(不对称类别拆分,PMID 12659652;亚型差异,PMID 34111156);家族史阳性传递的皮纹相似度异常(PMID 40918011);相关特征下置换重要性与SHAP的失真机制(PMID 38716264、37726680)。
待验证: 皮纹+PRS联合模型中增量NRI的「特征谱×亚组」双维定位——目前没有任何一项研究同时按皮纹特征族消融并按发病年龄/家族史/PRS分位分层报告NRI,本课题属直接可测的方法学空白。

L1 网络状态:该主题尚未进入 L1 对应网络(EDGE_TABLE 无皮纹-PRS联合模型/NRI增量边),本文证据等级因此封顶为 C,不构成已验证机制。

相关阅读

证据等级: C
参考文献: PMID 23116885, PMID 12659652, PMID 34111156, PMID 40918011, PMID 36652418, PMID 37925478, PMID 38758931, PMID 38716264, PMID 37726680

证据等级:A=有PubMed直接支撑,B=科学类比/间接证据,C=传统文化共识/初步探索


免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。

Signal Spectrum Localization of Incremental NRI in a Combined Dermal and PRS Model: Which Dermal Features and Disease Subgroups Drive the Increment

Evidence level: C

Reporting a single total increment from the combined model is insufficient—the critical threshold for determining whether this model possesses biological meaning lies in identifying which specific palmar crease features contribute the increment and in which disease subgroups these effects are localized.

Body

Fingerprint and palm crease patterns (dermatoglyphics) stabilize during fetal development between approximately 13 and 19 weeks, sharing the same developmental window with central neuronal migration; consequently, they are regarded as an external readout of prenatal developmental perturbations. Polygenic risk scores (PRS), by contrast, represent a genetic load read directly from the adult genome. One records what occurred within the uterus, while the other records what was brought by sperm and egg; theoretically, combining them into a single predictive model should yield complementary information. The problem is that current joint-model studies mostly report only a total AUC or NRI increment, never addressing two finer-grained questions: from which category of dermatoglyphic features does the increment primarily arise, and on which subset of individuals does it primarily fall?

The first question has precedents. A meta-analysis encompassing 22 studies found that the association spectrum between dermatoglyphics and schizophrenia is not uniform: only two “count-based” features—the total number of fingerprint ridges and the total A-B ridge count—reach statistical significance (albeit with small effect sizes), whereas features such as the atd angle, finger type category, and fluctuation asymmetry fail to reach significance (PMID 23116885). Earlier case-control studies further demonstrated the approach of “calculating separately by feature category”—testing directional asymmetry and fluctuation asymmetry independently, concluding that the two contribute structurally different signals (PMID 12659652). A 2021 clinical subtype study also revealed that different subtypes correspond to inconsistent combinations of dermatoglyphic features (PMID 34111156). In other words, dermatoglyphic signals are inherently “spectral”; lumping all features together to compute a total increment defaults to the assumption of a uniform spectrum—an assumption that is likely incorrect.

The second question has been addressed by cardiovascular PRS literature, which provides a standard operating procedure: the NRI increment of PRS in clinical risk models primarily falls on the “moderate-risk” population—low-risk individuals do not require reclassification, high-risk individuals already have sufficient clinical variables, and only the intermediate zone is where PRS proves useful (PMID 36652418, 37925478). Furthermore, studies have observed a “metric mismatch” where AUC remains nearly unchanged while NRI becomes significantly positive—indicating that the increment reflects improved ranking rather than enhanced discrimination (PMID 38758931). By this reasoning, the dermatoglyphic increment should also be stratified across disease subgroups: early-onset cases (where the neurodevelopmental perturbation window is purer), individuals with positive family history (where dermatoglyphic-genetic load interactions may exist; family transmission studies have indicated that dermatoglyphic similarity abnormally increases in affected parent-offspring pairs, PMID 40918011), and high-PRS individuals (where a ceiling effect may occur: the variance already captured by PRS means the remaining contribution of dermatoglyphics should shrink).

Methodologically, there is another pitfall to avoid: dermatoglyphic features are highly correlated (ridge counts of fingers on the same hand are nearly collinear). Performing permutation importance feature-by-feature will simultaneously underestimate contributions because correlated features “compete” for the importance signal. SHAP can decompose contributions, but results depend on the choice of conditional semantics. A more robust approach is whole-family ablation: removing all ridge counts, removing all asymmetry indices, and entering/exiting the model by feature family, directly observing changes in incremental NRI to avoid the correlation trap of feature-by-feature attribution (PMID 38716264, 37726680).

For readers of Yijing Studies: the cultural practice of “reading palm lines to determine fate” belongs to symbolic interpretation, whereas this discussion concerns statistical associations between quantifiable dermatoglyphic features and disease risk; the two are not the same.

Evidence and Limitations

Verified: In the palm print–schizophrenia association, ridge-line count features show the most robust effects (meta-analysis, PMID 23116885); PRS incremental NRI concentrates in intermediate-risk populations and can exhibit AUC stability alongside significant NRI gains (PMID 36652418, 38758931).
Partially Verified: Palm print feature categories contribute structurally distinct patterns (asymmetric category splitting, PMID 12659652; subtype differences, PMID 34111156); anomalous palm print similarity in positive family history transmission (PMID 40918011); distortion mechanisms of permutation importance and SHAP under correlated features (PMID 38716264, 37726680).
Pending Verification: Two-dimensional localization of incremental NRI in combined palm print+PRS models via “feature spectrum × subgroup” — currently no study simultaneously ablates by palm print feature families and reports NRI stratified by onset age/family history/PRS percentiles; this topic represents a directly measurable methodological gap.

L1 Network Status: This topic has not yet entered the L1 corresponding network (EDGE_TABLE lacks palm print-PRS joint model/NRI incremental edges); therefore, the evidence level for this paper is capped at C and does not constitute a verified mechanism.

Related Reading

Evidence level: C
References: PMID 23116885, PMID 12659652, PMID 34111156, PMID 40918011, PMID 36652418, PMID 37925478, PMID 38758931, PMID 38716264, PMID 37726680

Evidence level: A = direct PubMed support; B = scientific analogy or indirect evidence; C = traditional consensus or preliminary exploration.


Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *